Literature DB >> 29981383

Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.

Masataka Torigoe1, Kei Sakata2, Akina Ishii2, Shigeru Iwata3, Shingo Nakayamada3, Yoshiya Tanaka4.   

Abstract

Hydroxychloroquine is widely used for autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Although B cells contribute to the pathogenesis of these diseases, the action of hydroxychloroquine on B cells remains unclear. Here we examined the effects of hydroxychloroquine on functions of B cell subsets. Hydroxychloroquine efficiently inhibited the mammalian target of rapamycin complex 1, differentiation of CD19+IgD-CD27+ class-switched memory B cells to plasmablasts and their IgG production, under stimulation with CpG, a Toll-like receptor (TLR)-9 ligand. Hydroxychloroquine also inhibited CpG-induced production of interleukin-6 and tumor necrosis factor-α in B cell subsets. Taken together, hydroxychloroquine markedly suppresses the TLR9-mediated human B cell functions during inflammatory processes. Based on our results, we believe that hydroxychloroquine can be beneficial in the treatment of B cell-mediated autoimmune diseases.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Human B cell; Hydroxychloroquine; Plasmablast; Toll-like receptor 9

Mesh:

Substances:

Year:  2018        PMID: 29981383     DOI: 10.1016/j.clim.2018.07.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  21 in total

Review 1.  Toll-Like Receptors, Infections, and Rheumatoid Arthritis.

Authors:  Marina I Arleevskaya; R V Larionova; Wesley H Brooks; Eléonore Bettacchioli; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

2.  A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?

Authors:  Carlo Maria Rossi; Flavio Niccolò Beretta; Grazia Traverso; Sandro Mancarella; Davide Zenoni
Journal:  Clin Mol Allergy       Date:  2020-10-06

Review 3.  Cutaneous Lupus Erythematosus: Progress and Challenges.

Authors:  Amy J Petty; Lauren Floyd; Christopher Henderson; Matilda W Nicholas
Journal:  Curr Allergy Asthma Rep       Date:  2020-04-04       Impact factor: 4.806

4.  Therapeutic vaccines for aggressive B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ken H Young
Journal:  Leuk Lymphoma       Date:  2020-08-25

5.  Thymoma-associated multiorgan autoimmunity initially manifested by graft-versus-host disease-like erythroderma: Case report and possible therapeutic role of antimalarial drugs.

Authors:  Grace A Hile; Taylor Novice; Jeanne Kochkodan; May P Chan; Johann E Gudjonsson; Milad Eshaq
Journal:  JAAD Case Rep       Date:  2020-06-11

6.  Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation.

Authors:  Ryo Tanaka; Masanari Umemura; Masatoshi Narikawa; Mayu Hikichi; Kohei Osaw; Takayuki Fujita; Utako Yokoyama; Tomoaki Ishigami; Kouichi Tamura; Yoshihiro Ishikawa
Journal:  ESC Heart Fail       Date:  2020-01-27

Review 7.  Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis.

Authors:  Jaber Emami; Zahra Ansarypour
Journal:  Res Pharm Sci       Date:  2019-12-11

Review 8.  Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.

Authors:  Seidu A Richard; Sylvanus Kampo; Maite Esquijarosa Hechavarria; Marian Sackey; Alexis D B Buunaaim; Eugene Dogkotenge Kuugbee; Thomas Winsum Anabah
Journal:  J Immunol Res       Date:  2020-09-25       Impact factor: 4.818

Review 9.  Hydroxychloroquine in rheumatic autoimmune disorders and beyond.

Authors:  Eliise Laura Nirk; Fulvio Reggiori; Mario Mauthe
Journal:  EMBO Mol Med       Date:  2020-07-26       Impact factor: 12.137

10.  Predictive value of plasmacytoid dendritic cells and Toll-like receptor-9 regarding the treatment efficacy of interferon-α in HBeAg-positive chronic hepatitis B patients.

Authors:  Yue Chen; Jia-En Yang; Jing-Mo Tang; Qian-Guo Mao; Qi-Zhong Zheng; Ying Zheng
Journal:  Exp Ther Med       Date:  2019-11-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.